138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis

S Lu,J Wang,Y Yu,X Yu,Y Hu,Z Ma,X Li,W He,Y Bao,M Wang

doi:10.1016/j.iotech.2022.100250

138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis

S Lu, J Wang + Show 8 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100250

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
Citations: 1	License type: cc-by-nc-nd

Affiliation: Hubei Cancer Hospital, Shanghai Chest Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital, First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital of Harbin Medical University, Peking Union Medical College Hospital, Cancer Hospital of Chinese Academy of Medical Sciences

#Advanced Non-squamous Non-small Cell Lung #Non-squamous Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Interim analysis of the open-label phase 3 RATIONALE-304 study (NCT03663205) demonstrated clinical benefit of tislelizumab (TIS) plus chemotherapy (chemo) as first-line (1L) therapy in patients with advanced nsq-NSCLC vs chemo alone, with significantly improved progression-free survival (PFS) and a manageable safety profile. Here, we report the updated results.

Full Text